Synteract, Inc. (San Diego) and Mpex Pharmaceuticals, Inc. Team Up for Cystic Fibrosis Walk and Cure
5/18/2011 10:23:36 AM
More...
|
Axcan Pharma (AXCA) to Buy Mpex Pharmaceuticals, Inc. for Phase III-Stage Aerosol Antibiotic; Mpex Plans to Spin Out the Aeroquin Assets into a New Company
4/14/2011 10:55:47 AM
More...
|
Mpex Pharmaceuticals, Inc. Initiates Phase 3 Clinical Trial Program with Aeroquin(TM) for the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
1/10/2011 7:22:28 AM
More...
|
Mpex Pharmaceuticals, Inc. Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
5/17/2010 8:59:02 AM
More...
|
Mpex Pharmaceuticals, Inc. Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma's eFlow Technology
9/15/2009 7:59:58 AM
More...
|
Mpex Pharmaceuticals, Inc. Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) Treatment in Cystic Fibrosis Patients; Primary Endpoint Met
9/10/2009 6:48:15 AM
More...
|
Mpex Pharmaceuticals, Inc. Names Mark Wiggins Chief Business Officer
4/20/2009 10:05:48 AM
More...
|
Mpex Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
11/3/2008 8:37:01 AM
More...
|
Mpex Pharmaceuticals, Inc. Presents New Data on MP-376 in Cystic Fibrosis
10/23/2008 10:05:03 AM
More...
|
Mpex Pharmaceuticals, Inc. Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
6/25/2008 7:49:18 AM
More...
|
|